<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090789</url>
  </required_header>
  <id_info>
    <org_study_id>01-002609</org_study_id>
    <nct_id>NCT03090789</nct_id>
  </id_info>
  <brief_title>FA Clinical Outcome Measures</brief_title>
  <acronym>FA-COMS</acronym>
  <official_title>Clinical Outcome Measures in Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Friedreich's Ataxia Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter natural history study aims to expand the network of clinical research
      centers in FA, and to provide a framework for facilitating therapeutic interventions. In
      addition, this study will lead to the development of valid yet sensitive clinical measures
      crucial to outcome assessment of patients with Friedreich's Ataxia. This study will support
      genetic modifier studies, biomarker studies, and frataxin protein level assessments by
      building a sample repository.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Friedreich's ataxia (FA) is a rare autosomal recessive degenerative disorder characterized by
      ataxia, dysarthria, sensory loss, diabetes and cardiomyopathy. The discovery of the abnormal
      gene in FA and its product (frataxin) has provided insight into possible pathophysiological
      mechanisms and novel approaches to treatments in this disease. While such methods for
      assessing disease progression may be useful, evaluation in clinical trials will require
      specific clinical outcome measures.

      This is a multicenter natural history study which aims to expand the network of clinical
      research centers specializing in Friedreich's Ataxia and to advance clinical care, research
      and therapeutic approaches in FA through the development and validation of clinical outcome
      measures. Study sites aim to collect quantitative serial clinical data on patients with FA
      and expand the existing research network. In addition, the study will support various genetic
      modifier studies, biomarker studies, and frataxin protein level assessments in patients with
      FA, in carriers, and in controls.

      This study will recruit up to 1500 patients with Friedreich ataxia worldwide, to be assessed
      annually for up to 15 years. All individuals with a genetic or clinical diagnosis of FA can
      participate.

      Study participation involves yearly assessments of a core set of clinical measures and
      quality of life assessment measures in addition to optional collection of a cheek swab and/or
      blood sample.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2001</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Friedreich Ataxia Rating Scale</measure>
    <time_frame>once every 1 year</time_frame>
    <description>rating scale based on clinical neurologic examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>9-hole peg test</measure>
    <time_frame>once every 1 year</time_frame>
    <description>timed test of fine motor skills performed as a set of four trials (two trials per hand), for patients with FA who are able to complete this testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>timed 25 foot walk</measure>
    <time_frame>once every 1 year</time_frame>
    <description>timed 25 foot walk is performed twice for patients with FA who are able to complete this testing. Assistive devices such as canes, service dogs, walkers, or crutches are permitted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision assessment</measure>
    <time_frame>once every 1 year</time_frame>
    <description>High and low contrast visual acuity tested on patients with FA who are able to perform this test. Glasses or contact lenses are permitted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires</measure>
    <time_frame>once every 1 year</time_frame>
    <description>a set of quality of life questionnaires is administered for study participants with Friedreich ataxia. Questionnaires include items such as activities of daily living, overall opinion on health and function, and fatigue-related questions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Optional sample collection</measure>
    <time_frame>once every 1 year</time_frame>
    <description>study participants will be asked to provide a cheek swab and/or blood sample for a variety of different measures including frataxin protein level assessments or other biomarker tests</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Friedreich Ataxia</condition>
  <condition>Neuro-Degenerative Disease</condition>
  <arm_group>
    <arm_group_label>Study Participant</arm_group_label>
    <description>Study participants can be individuals with either a clinical diagnosis or genetic confirmation of Friedreich ataxia. In addition, this study enrolls Friedreich ataxia carriers and unaffected controls.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Optional sample collection offered to study participants; whole blood and/or cheek swab may
      be collected as a one-time procedure.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with either a clinical diagnosis or genetic test confirmation of Friedreich
        ataxia. Study also accepts carriers of Friedreich ataxia along with healthy volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females age 4 to 80 years.

          2. Genetically confirmed diagnosis of FA (for carrier/control cheek swab and blood
             samples this is not required).

          3. Clinically confirmed diagnosis of FA, pending confirmatory genetic testing through a
             commercial or research laboratory (for carrier/control cheek swab and blood samples
             this is not required).

          4. Parental/guardian permission (informed consent) and if appropriate, child assent.

        Exclusion Criteria:

        1) Signs or symptoms of severe cardiomyopathy (such as congestive heart failure)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lynch, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Farmer, MS CGC</last_name>
    <phone>484-879-6160</phone>
    <email>jen.farmer@curefa.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Ataxia Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Westley Ulit</last_name>
      <phone>310-206-8153</phone>
      <email>WUlit@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Perlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida - Neurology</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aika Konn, BA</last_name>
      <phone>352-273-6003</phone>
      <email>aika.konn@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>SH Subramony, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USF Ataxia Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avery Thomson, MS</last_name>
      <phone>561-400-3576</phone>
      <email>averythomson@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa Zesiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Neurology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca S McMurray, RN</last_name>
      <phone>404-712-7013</phone>
      <email>rmcmurr@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Wilmot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa, Stead Family Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Recker, RN</last_name>
      <phone>319-335-6073</phone>
      <email>diane-recker@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Neurology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louisa Mezache</last_name>
      <phone>614-685-3030</phone>
      <email>louisa.mezache@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Chad Hoyle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia - Neurology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Hauser, MS LCGC</last_name>
      <phone>267-426-7538</phone>
      <email>FAPROGRAM@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>David Lynch, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneieve Tai</last_name>
      <phone>61 8341 6374</phone>
      <email>geneieve.tai@mcri.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Louise Corben, PhD</last_name>
      <phone>61 3 8341 6228</phone>
      <email>louise.corben@vcgs.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Delatycki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winnie Lam</last_name>
      <phone>416-813-6389</phone>
      <email>winnie.lam@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Grace Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich Ataxia</keyword>
  <keyword>Neuro-degenerative disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

